Hodgkin Lymphoma - Pipeline Review, Q1 2011

Global Markets Direct, January 2011, Pages: 149

Hodgkin Lymphoma - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Hodgkin Lymphoma - Pipeline Review, Q1 2011', provides an overview of the Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma. 'Hodgkin Lymphoma - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Hodgkin Lymphoma.
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hodgkin Lymphoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Hodgkin Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hodgkin Lymphoma Overview
Therapeutics Development
An Overview of Pipeline Products for Hodgkin Lymphoma
Hodgkin Lymphoma Therapeutics under Development by Companies
Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Hodgkin Lymphoma Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Amgen Inc.
Seattle Genetics, Inc.
Merck & Co., Inc.
ZIOPHARM Oncology, Inc.
Novartis AG
Celgene Corporation
Onyx Pharmaceuticals, Inc.
4SC AG
Hana Biosciences, Inc.
Allos Therapeutics, Inc
Cytokinetics, Inc
Pharmacyclics, Inc.
Dendreon Corporation
Baylor College of Medicine
Affimed Therapeutics AG
Italfarmaco S.p.A.
MAT Biopharma
S-BIO Pte Ltd
Gemin X Pharmaceuticals
Syndax Pharmaceuticals, Inc.
Xencor, Inc.
TaiGen Biotechnology Co., Ltd.
Archer Biosciences, Inc
American Scitech Inc.
Universities/Institutes Involved in Hodgkin Lymphoma Therapeutics Development
Hodgkin Lymphoma Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Adriamycin + Bleomycin + Vinblastine + Dacarbazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brentuximab Vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LBH589 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
ABVD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABVD Regimen + Carmustine + Etoposide + Cyclophosphamide + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adriamycin + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Etoposide + Methylprednisolone + Vincristine Sulfate + Vindesine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adriamycin + Bleomycin + Vinblastine + DTIC + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adriamycin + Bleomycin + Vinblastine + Etoposide + Procarbazine + Prednisone + Vincristine + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adriamycin + Bleomycin + Vincristine + Dacarbazine for Hodgkin's Lymphoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEACOPP + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone + goserelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin sulfate + ABVD regimen + dacarbazine + doxorubicin hydrochloride + vinblastine + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin sulfate + ABVD regimen + carmustine + cyclophosphamide + dacarbazine + doxorubicin hydrochloride + etoposide + vinblastine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin sulfate + cyclophosphamide + doxorubicin hydrochloride + etoposide + ifosfamide + prednisone + vincristine sulfate + vinorelbine ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin sulfate + cyclophosphamide + doxorubicin hydrochloride + etoposide + prednisolone + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin sulfate + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin sulfate + cyclophosphamide + doxorubicin hydrochloride + etoposide + prednisone + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin sulfate + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine sulfate + Vinorelbine ditartrate + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin sulfate + filgrastim + cyclophosphamide + dacarbazine + doxorubicin hydrochloride + etoposide + prednisone + procarbazine hydrochloride + vinblastine + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + Cisplatin + Cytarabine + Dexamethasone + Adiramycin + Etoposide + Gemcitabine Hydrochloride + Ifosfamide + Melphalan + Methylprednisolone + Mitoguazone + Vindesine + Vinorelbine Ditartrate + Allogeneic Stem Cell Transplantation + Autologous Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Bleomycin + Vinblastine + Dacarbazine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Vinblastine + Vincristine + Bleomycin + Mechlorethamine + Etoposide + Prednisone + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cisplatin + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Etoposide Phosphate + Ifosfamide + Prednisone + Vincristine Sulfate + Vinorelbine Ditartrate + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + methotrexate + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + cyclophosphamide + cytarabine + dexamethasone + doxorubicin hydrochloride + methotrexate + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ifosfamide + Etoposide + Prednisone + Doxorubicin hydrochloride + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Cytarabine + Melphalan + Radiation threapy + Stem cell transplantion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ifosfamide + Etoposide + Prednisone + Doxorubicin hydrochloride + Bleomycin + Vinblastine + Dacarbazine + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone + Vincristine + Doxorubicin hydrochloride + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone + Vincristine + Doxorubicin hydrochloride + Etoposide + Dacarbazine + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone + Vincristine + Doxorubicin hydrochloride + Etoposide + Procarbazine hydrochloride + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone/Predinosolone + Vincristine + Doxorubicin + Etoposide + Cyclophosphamide + Dacarbazine + Radiation Therapy + Ifosfamide + Bleomycin + Vinblastine + Carmustine + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone/Predinosolone + Vincristine + Doxorubicin + Etoposide + Procarbazine Hydrochloride + Cyclophosphamide + Radiation Therapy + Ifosfamide + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone/Predinosolone + Vincristine + Doxorubicin + Etoposide + Radiation Therapy + Ifosfamide + Bleomycin + Vinblastine + Dacarbazine + Carmustine + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiotepa + Cyclophosphamide + ATG + OKT3 + Rituximab + Radiation therapy + Stem cell tranplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Hodgkin Lymphoma - Featured News
Dec 06, 2010: Novartis Phase II LBH589 Data Show Substantial Disease Control And Tumor Reduction In Hodgkin Lymphoma
Dec 06, 2010: Methylgene Reports Favorable Final Phase II Clinical Data Of Mocetinostat In Hodgkin Lymphoma
Dec 06, 2010: Aeterna Zentaris Presents Phase II Data Of Perifosine In Combination With Sorafenib In Advanced Leukemia And Lymphoma
Dec 05, 2010: Seattle Genetics And Millennium Report Positive Data From Pivotal Trial Of Brentuximab Vedotin In Hodgkin Lymphoma
Dec 01, 2010: 4SC To Present Initial Phase II Data Of Resminostat In Hodgkin’s Lymphoma Patients At ASH Annual Meeting
Nov 29, 2010: Calistoga Announces Oral And Poster Presentations On CAL-101 At ASH Annual Meeting
Nov 29, 2010: Methylgene To Present Final Phase II Clinical Data Of Mocetinostat At ASH Annual Meeting
Nov 08, 2010: Seattle Genetics And Millennium To Present Brentuximab Vedotin Clinical Data At American Society Of Hematology Annual Meeting
Nov 03, 2010: Seattle Genetics And Millennium Report Data From Brentuximab Vedotin Phase I Clinical Trial
Oct 26, 2010: 4SC Presents Initial Phase II Data Of Resminostat At International Symposium On Hodgkin Lymphoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hodgkin Lymphoma, 2011
Products under Development for Hodgkin Lymphoma – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Amgen Inc., 2011
Seattle Genetics, Inc., 2011
Merck & Co., Inc., 2011
ZIOPHARM Oncology, Inc., 2011
Novartis AG, 2011
Celgene Corporation, 2011
Onyx Pharmaceuticals, Inc., 2011
4SC AG, 2011
Hana Biosciences, Inc., 2011
Allos Therapeutics, Inc, 2011
Cytokinetics, Inc, 2011
Pharmacyclics, Inc., 2011
Dendreon Corporation, 2011
Baylor College of Medicine, 2011
Affimed Therapeutics AG, 2011
Italfarmaco S.p.A., 2011
MAT Biopharma, 2011
S-BIO Pte Ltd, 2011
Gemin X Pharmaceuticals, 2011
Syndax Pharmaceuticals, Inc., 2011
Xencor, Inc., 2011
TaiGen Biotechnology Co., Ltd., 2011
Archer Biosciences, Inc, 2011
American Scitech Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Hodgkin Lymphoma, 2011
Products under Development for Hodgkin Lymphoma – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Customers who bought this item also bought

• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010
• Global Non-hodgkin's Lymphoma Pipeline Capsule - 2013
• University of Cologne - Developmental Therapeutics Review - Q1 2011
• Brain Cancer - Pipeline Review, H2 2012
• Global Non-Hodgkin's Lymphoma Epidemiology and Patient Flow Analysis - 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Global Non-hodgkin's Lymphoma Drug Pipeline Capsule - 2012 Update
• T-Cell Lymphomas - Pipeline Review, Q4 2010